Access to reimbursement of interferon-free all-oral regimens for patients with chronic Hepatitis C in Austria

Background: At present, reimbursement of interferon-free all-oral regimens for chronic hepatitis C in Austria is limited to patients with advanced liver fibrosis. The aim of this study was to assess the distribution of stages of fibrosis and hence, access to interferon-free regimens in patients presenting at our outpatient clinic. Patients and Methods: A total of 257 consecutive patients [m/f: 161/96, mean age: 51 ± 11 years, GT 1: 11 (4.3%), GT 1a: 60 (23.3%), GT 1b: 59 (23.0%), GT2: 5 (1.9%), GT 3: 42 (16.3%), GT 4: 21 (8.2%), GT not yet available: 59 (23.0%)] who presented at our outpatient clinic between 26.…